Duncan McHale - May 7, 2023 Form 4 Insider Report for Evelo Biosciences, Inc. (EVLO)

Role
Chief Medical Officer
Signature
/s/ Marella Thorell, Attorney-in-Fact for Duncan McHale
Stock symbol
EVLO
Transactions as of
May 7, 2023
Transactions value $
$0
Form type
4
Date filed
5/9/2023, 04:08 PM
Previous filing
Feb 9, 2023
Next filing
May 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVLO Common Stock Options Exercise +130K +379.61% 164K May 7, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLO Restricted Stock Units Options Exercise $0 -130K -25% $0.00 390K May 7, 2023 Common Stock 130K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
F2 The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date.